Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglu

Novo Nordisk · Phase 2 · Completed · Enrollment 626

NCT06131372

EudraCT 2023-505857-42

ArmPopulationDoseWeeksEstimandWeight change
CagriSemaObesity + T2Dn/r35n/rn/r
SemaglutideObesity + T2Dn/r35n/rn/r
CagrilintideObesity + T2Dn/r35n/rn/r
PlaceboObesity + T2Dn/r35n/rn/r